Herein, a PSMA (−) prostate cancer specific targeted and intracellular reactive oxygen species (ROS) amplification for ROS-responsive self-accelerating drug release nanoplatform (ATD-NPs) was developed. This evidence concerns the gene FOLH1 and prostate cancer.